GlassScriptPhysician profile
Manoucher Jalali
NPI 1033141171
$547.27
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $126 · 2021: $51.61 · 2022: $167.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $256.63 | 2019-2022 | |
| Organogenesis INC. | $148.89 | 2019-2022 | |
| Misonix INC | $39.44 | 2019-2020 | |
| Integra Lifesciences Corporation | $36.78 | 2019 | |
| Abbvie INC. | $21.57 | 2022 | |
| Osiris Therapeutics INC. | $18.82 | 2019 | |
| Nabriva Therapeutics, Plc | $12.81 | 2021 | |
| Paratek Pharmaceuticals, INC. | $12.33 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manoucher Jalali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.